NEJM (@NEJM) / X

Pinned

In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz

A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.

Duchenne muscular dystrophy, the most common childhood muscular dystrophy, with an estimated prevalence of 1 in 5000 boys 5 to 9 years of age, is a recessive degenerative disorder caused by variants in the dystrophin gene that lead to deficiency of dystrophin. Learn more in “A

An illustrated diagram of multisystem findings in patients with Duchenne Muscular Dystrophy. The image highlights physical features such as shoulder and arm positioning, a protruding belly, calf muscles with pseudohypertrophy, and a waddling gait. Annotations describe muscle weakness, respiratory challenges, positional deformity, and difficulty maintaining balance, leading to frequent falls.

The STAREE trial tested whether atorvastatin prevents first major cardiovascular events and extends disability-free survival in adults 70 years and older without cardiovascular disease. Research findings are summarized in a new Quick Take video. nej.md/4xXoFIG

Clockwise from top left: A box labeled "Atorvastatin" with two pills is depicted; an illustration showing a heart with an exclamation mark; a silhouette of a patient with a disability; and a group of five silhouettes representing older patients.

Recently launched smart vaping devices provide financial incentives tethered to use or engagement metrics. The authors of a new Perspective argue that the addictive potential of such devices poses public health concerns. Read the full Perspective: nej.md/46O45iK

A 23-year-old man was brought to the ED after intentional ingestion of 2000 mg of sertraline. Six hours after ingestion, spontaneous and sustained, inducible clonus and patellar hyperreflexia were noted in his legs (shown in a video). Read the full case details in the Images in

Three still images from the Images in Clinical Medicine article "Serotonin Syndrome." The stills are from a video showing sustained, inducible clonus and patellar hyperreflexia noted in both legs of a patient.